Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis

Tomas Mlcoch (), Jan Tuzil, Liliana Sedova, Jiri Stolfa, Monika Urbanova, David Suchy, Andrea Smrzova, Jitka Jircikova, Tereza Hrnciarova, Karel Pavelka and Tomas Dolezal
Additional contact information
Tomas Mlcoch: Institute of Health Economics and Technology Assessment
Jan Tuzil: Institute of Health Economics and Technology Assessment
Liliana Sedova: Institute of Rheumatology
Jiri Stolfa: Institute of Rheumatology
Monika Urbanova: Institute of Rheumatology
David Suchy: University Hospital Plzen
Andrea Smrzova: University Hospital Olomouc
Jitka Jircikova: Institute of Health Economics and Technology Assessment
Tereza Hrnciarova: Institute of Health Economics and Technology Assessment
Karel Pavelka: Institute of Rheumatology
Tomas Dolezal: Institute of Health Economics and Technology Assessment

The Patient: Patient-Centered Outcomes Research, 2018, vol. 11, issue 3, No 7, 329-340

Abstract: Abstract Background Clinical trials and observational studies lacking measures of health-related quality of life (QoL) are often inapplicable when conducting cost-effectiveness analyses using quality-adjusted life-years (QALYs). The only solution is to map QoL ex post from additionally collected clinical outcomes and generic QoL instruments. Nonetheless, mapping studies are absent in psoriatic arthritis (PsA). Methods In this 2-year, prospective, multicentre, non-interventional study of PsA patients, EQ-5D and key clinical parameters such as Disease Activity in PsA (DAPsA), clinical DAPsA (cDAPsA; DAPsA without C-reactive protein [CRP]), and Health Assessment Questionnaire disability index (HAQ) were collected. We employed a linear mixed-effect regression model (ME) of the longitudinal dataset to explore the best predictors of QoL. Results A total of 228 patients were followed over 873 appointments/observations. DAPsA, cDAPsA and HAQ were stable and highly significant predictors of EQ-5D utilities in both cross-sectional and longitudinal analyses. The best prediction was provided using a linear ME with HAQ and cDAPsA or DAPsA. A HAQ increase of 1 point represented a decrease in EQ-5D by −0.204 or −0.203 (p

Date: 2018
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40271-017-0285-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:11:y:2018:i:3:d:10.1007_s40271-017-0285-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-017-0285-1

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().